文献速递慢性肾脏病肾血管病与高血压

稳定冠心病合并慢性肾功能不全患者的10年随访结局:MASS II试验

Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

基于MASS II随机试验611例稳定冠心病患者,按基线eGFR分为肾功能保留、轻度CKD和中度CKD三组,随访10年。主要终点(总死亡+心肌梗死)发生率随肾功能下降而升高(29.5%、32.4%、44.7%,P=0.02)。在轻度CKD患者中,PCI和CABG较单纯药物治疗显著降低主要事件风险。

要点

  • 轻度CKD患者中,PCI和CABG的主要事件风险显著低于单纯药物治疗。
  • 肾功能保留者三种治疗策略的结局无显著差异。
  • 中度CKD患者趋势相似但未达统计学显著性。

核心结论

  • 在轻度CKD的稳定冠心病患者中,随访超过10年,PCI和CABG较单纯药物治疗与更低的事件率相关。
  • 中度CKD患者的获益趋势相似但未达到统计学显著性,需更多研究确认。

研究设计与样本

  • MASS II随机试验的10年随访分析,共纳入611例稳定冠心病患者,随机接受单纯药物治疗、PCI或CABG。
  • 根据基线eGFR分为肾功能保留(≥90)、轻度CKD(89-60)和中度CKD(59-30 mL/min/1.73 m2)三组。
  • 主要终点为总死亡和心肌梗死的复合终点,采用比例风险回归分析。

主要发现

  • 611例中,112例(18%)肾功能保留,349例(57%)轻度CKD,150例(25%)中度CKD。
  • 主要终点发生率在肾功能保留、轻度CKD和中度CKD组分别为29.5%、32.4%和44.7%(P=0.02)。
  • 总死亡率在肾功能保留、轻度CKD和中度CKD组分别为18.7%、23.8%和39.3%(P=0.001)。
  • 轻度CKD组中,主要事件率PCI为29.4%、CABG为29.1%、药物治疗为41.1%(P=0.006);PCI vs 药物治疗调整HR=0.26(95%CI 0.07-0.88;P=0.03),CABG vs 药物治疗调整HR=0.48(95%CI 0.31-0.76;P=0.002)。
  • 轻度CKD组中,药物治疗组死亡率28.6%,高于PCI组24.1%和CABG组19.0%(P=0.015);CABG vs 药物治疗调整HR=0.44(95%CI 0.25-0.76;P=0.003),PCI vs 药物治疗调整HR=0.56(95%CI 0.07-4.28;P=0.58)。

临床怎么用

  • 对稳定冠心病合并轻度CKD的患者,可考虑血运重建(PCI或CABG)而非仅药物治疗,以降低长期事件风险。
  • 中度CKD患者的血运重建获益尚不明确,需个体化决策并等待更多证据。

局限性

  • 中度CKD亚组的事件差异未达到统计学显著性,可能受样本量限制。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease (CKD) is associated with a worse prognosis in patients with stable coronary artery disease (CAD); however, there is limited randomized data on long-term outcomes of CAD therapies in these patients. We evaluated long-term outcomes of CKD patients with CAD who underwent randomized therapy with medical treatment (MT) alone, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). METHODS: Baseline estimated glomerular filtration rate (eGFR) was obtained in 611 patients randomized to one of three therapeutic strategies in the Medicine, Angioplasty, or Surgery Study II trial. Patients were categorized in preserved renal function and mild or moderate CKD groups depending on their eGFR (≥90, 89-60 and 59-30 mL/min/1.73 m2, respectively). The primary clinical endpoint, a composite of overall death and myocardial infarction, and its individual components were analyzed using proportional hazards regression (Clinical Trial registration information: http://www.controlled-trials.com. Registration number: ISRCTN66068876). RESULTS: Of 611 patients, 112 (18%) had preserved eGFR, 349 (57%) mild dysfunction and 150 (25%) moderate dysfunction. The primary endpoint occurred in 29.5, 32.4 and 44.7% (P = 0.02) for preserved eGFR, mild CKD and moderate CKD, respectively. Overall mortality incidence was 18.7, 23.8 and 39.3% for preserved eGFR, mild CKD and moderate CKD, respectively (P = 0.001). For preserved eGFR, there was no significant difference in outcomes between therapies. For mild CKD, the primary event rate was 29.4% for PCI, 29.1% for CABG and 41.1% for MT (P = 0.006) [adjusted hazard ratio (HR) = 0.26, 95% confidence interval (CI) 0.07-0.88; P = 0.03 for PCI versus MT; and adjusted HR = 0.48; 95% CI 0.31-0.76; P = 0.002 for CABG versus MT]. We also observed higher mortality rates in the MT group (28.6%) compared with PCI (24.1%) and CABG (19.0%) groups (P = 0.015) among mild CKD subjects (adjusted HR = 0.44, 95% CI 0.25-0.76; P = 0.003 for CABG versus MT; adjusted HR = 0.56, 95% CI 0.07-4.28; P = 0.58 for PCI versus MT). Results were similar with moderate CKD group but did not achieve significance. CONCLUSIONS: Coronary interventional therapy, both PCI and CABG, is associated with lower rates of events compared with MT in mild CKD patients >10 years of follow-up. More study is needed to confirm these benefits in moderate CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lima EG, Charytan DM, Hueb W, et al. Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial. Nephrol Dial Transplant. 2020. PMID: 30590726. doi:10.1093/ndt/gfy379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。